$0.65
12.46%
Nasdaq, Nov 17, 04:00 pm EST.
ISIN
US88875G1013
Symbol
TLSA

Tiziana Life Sciences PLC Sponsored ADR Stock price

$0.65
-0.36 35.84% 1M
-0.70 52.00% 6M
-0.84 56.51% YTD
-1.04 61.66% 1Y
+0.09 15.32% 3Y
-0.74 53.38% 5Y
-1.00 60.67% 10Y
-1.00 60.67% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
+0.07 12.46%
ISIN
US88875G1013
Symbol
TLSA
Industry

Is Tiziana Life Sciences PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$83.1m
Enterprise Value
$79.6m
Net debt
positive
Cash
$4.0m
Shares outstanding
120.5m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
1,662.9
Financial Health
Equity Ratio
0.5%
Return on Equity
-
ROCE
-7,286.9%
ROIC
9,605.5%
Debt/Equity
8.8
Share-Based Compensation & Dilution
SBC | % of Revenue
$3.2m | -
SBC as % of FCF
-
SBC Growth 1Y
24.5%
Share Count Growth 1Y
8.1%
Shareholder Yield
-8.1%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-20.9m
EBIT
$-21.1m
Net Income
$-18.4m
Free Cash Flow | ex SBC
$-12.9m | $-16.1m
Growth
Revenue | estimate
- | -
EBITDA
-33.4%
EBIT
-33.8%
Net Income
-55.4%
Free Cash Flow
-730.3%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-0.2
FCF per Share
$-0.1
Short interest
8.0%
Employees
10
Rev per Employee
-

Tiziana Life Sciences PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Tiziana Life Sciences PLC Sponsored ADR forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Tiziana Life Sciences PLC Sponsored ADR forecast:

Buy
88%
Hold
13%

Tiziana Life Sciences PLC Sponsored ADR Events

Past Events
NOV
9
Special Call - Tiziana Life Sciences Ltd
9 days ago

Financial data from Tiziana Life Sciences PLC Sponsored ADR

Dec '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense 10 10
97% 97%
-
-21 -21
33% 33%
-
- Depreciation and Amortization 0.23 0.23
92% 92%
-
EBIT (Operating Income) EBIT -21 -21
34% 34%
-
Net Profit -18 -18
55% 55%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tiziana Life Sciences PLC Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tiziana Life Sciences PLC Sponsored ADR Stock News

Neutral
GlobeNewsWire
●
9 days ago
BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today provided additional context on the positive topline results from its Phase 2a INFORM-MS trial, bui...
Neutral
GlobeNewsWire
●
13 days ago
BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced that it will host a conference call and webcast with Key Opinion Leaders (KOLs) to discu...
Positive
Reuters
●
16 days ago
Tiziana Life Sciences said on Monday its experimental therapy for a progressive form of ​multiple sclerosis with no approved treatments ‌reduced brain inflammation and showed a favorable safety profile in a mid-stage trial.
More Tiziana Life Sciences PLC Sponsored ADR News

Company Profile

Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Mr. Elrifi
Employees 10
Founded 1998
Website www.tizianalifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today